MGX — Metagenomi Therapeutics Share News
0.000.00%
Last trade - 00:00- $30.43m
- -$90.23m
- $25.21m
Metagenomi Q2 net loss widens cash runway seen through 2027
Metagenomi Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Metagenomi Announces Corporate Name Change To Metagenomi Therapeutics, Inc. And Highlights Recent Business Milestones And 2026 Corporate Outlook
U.S. RESEARCH ROUNDUP- Autodesk, Crowdstrike, Zscaler
Brief: Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human Primates
Metagenomi taps Amazon's custom chips to develop gene-editing tools
Metagenomi Inc reports results for the quarter ended June 30 - Earnings Summary
Metagenomi Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Metagenomi Reports Business Updates And First Quarter 2025 Financial Results
Brief: Metagenomi files for mixed shelf offering of up to $250 mln - SEC filing
Brief: Metagenomi Reports Business Updates And Second Quarter 2024 Results
U.S. RESEARCH ROUNDUP- Mastercard, Metagenomi, Ziff Davis
U.S. RESEARCH ROUNDUP-American Express, Cintas, Kimberly-Clark
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Moderna, Bayer-backed Metagenomi tumbles after bottom-range IPO pricing
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut
Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln (updated)
Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln
Brief: Metagenomi Announces Pricing Of Initial Public Offering